Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 183817

MULTIDRUG RESISTANCE IN MULTIPLE MYELOMA. IS THERE A PLACE FOR IDARUBICIN IN CHEMOTHERAPY?


Ajduković, Radmila; Majdak, Patricia; Bendelja, Krešo; Pejša, Vlatko; Svoboda-Beusan, Ivna
MULTIDRUG RESISTANCE IN MULTIPLE MYELOMA. IS THERE A PLACE FOR IDARUBICIN IN CHEMOTHERAPY? // Liječ Vjesn 125 (S3)
Opatija, Hrvatska, 2003. str. 99-99 (predavanje, nije recenziran, sažetak, znanstveni)


CROSBI ID: 183817 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
MULTIDRUG RESISTANCE IN MULTIPLE MYELOMA. IS THERE A PLACE FOR IDARUBICIN IN CHEMOTHERAPY?

Autori
Ajduković, Radmila ; Majdak, Patricia ; Bendelja, Krešo ; Pejša, Vlatko ; Svoboda-Beusan, Ivna

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Liječ Vjesn 125 (S3) / - , 2003, 99-99

Skup
4. Hrvatski kongres hematologa i transfuziologa s međunarodnim sudjelovanjem

Mjesto i datum
Opatija, Hrvatska, 23-26.10.2003

Vrsta sudjelovanja
Predavanje

Vrsta recenzije
Nije recenziran

Ključne riječi
MDR; Multiple myeloma; Idarubicin

Sažetak
Background: Poor response to chemotherapy in multiple myeloma (MM) has been associated with the development of multidrug resistance (MDR) primarily following the increase of P-glycoprotein (Pgp) expression. Therefore, the need for the new chemotherapy protocols with MDR-independent substrates has emerged. Study: Pgp phenotype and function of bone marrow cells during the follow-up of 78 consecutive MM patients, differing in the clinical stage and disease duration, had been analysed. The patients were treated according to the standard MM chemotherapy protocols, also including a small group of patients treated with VID (modified VAD) protocol (vincristine, idarubicin, dexamethasone), MDR-independent idarubicin replacing the MDR-dependent adriamycin (1). Results: Pgp expression on plasma cells increased with clinical stage of disease: the highest in clinical stage III (p<0.046). On the same cell population, the MDR-dependent treatment increased Pgp expression (p<0.003). The plasma cell population expressing Pgp increased with the lack of response to treatment (CR vs. NR p<0.023), and with the fatal outcome (p<0.001), associating the size of the plasma cell population to the seriousness of the patients condition. Despite their high Pgp expression, the patients on VID protocol had significantly (p<0.005) smaller plasma cell population, further decreasing with the duration of the VID therapy (p<0.001). Conclusion: Our preliminary results indicate that by using idarubicin to circumvent MDR, the modified VID protocol might enhance chemotherapeutic efficacy in the treatment of MM. 1. Leukemia Research 1999 ; 23: 539-548.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti, Kliničke medicinske znanosti



POVEZANOST RADA


Projekti:
0021001

Ustanove:
Imunološki zavod d.d.

Profili:

Avatar Url Ivna Svoboda-Beusan (autor)

Avatar Url Krešo Bendelja (autor)

Avatar Url Vlatko Pejša (autor)


Citiraj ovu publikaciju

Ajduković, Radmila; Majdak, Patricia; Bendelja, Krešo; Pejša, Vlatko; Svoboda-Beusan, Ivna
MULTIDRUG RESISTANCE IN MULTIPLE MYELOMA. IS THERE A PLACE FOR IDARUBICIN IN CHEMOTHERAPY? // Liječ Vjesn 125 (S3)
Opatija, Hrvatska, 2003. str. 99-99 (predavanje, nije recenziran, sažetak, znanstveni)
Ajduković, R., Majdak, P., Bendelja, K., Pejša, V. & Svoboda-Beusan, I. (2003) MULTIDRUG RESISTANCE IN MULTIPLE MYELOMA. IS THERE A PLACE FOR IDARUBICIN IN CHEMOTHERAPY?. U: Liječ Vjesn 125 (S3).
@article{article, year = {2003}, pages = {99-99}, keywords = {MDR, Multiple myeloma, Idarubicin}, title = {MULTIDRUG RESISTANCE IN MULTIPLE MYELOMA. IS THERE A PLACE FOR IDARUBICIN IN CHEMOTHERAPY?}, keyword = {MDR, Multiple myeloma, Idarubicin}, publisherplace = {Opatija, Hrvatska} }
@article{article, year = {2003}, pages = {99-99}, keywords = {MDR, Multiple myeloma, Idarubicin}, title = {MULTIDRUG RESISTANCE IN MULTIPLE MYELOMA. IS THERE A PLACE FOR IDARUBICIN IN CHEMOTHERAPY?}, keyword = {MDR, Multiple myeloma, Idarubicin}, publisherplace = {Opatija, Hrvatska} }




Contrast
Increase Font
Decrease Font
Dyslexic Font